Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team
Eksterne analyser

Lipum: Finding financial support - VH Corp

Lipum

Dette er en ekstern analyse og afspejler ikke nødvendigvis vores perspektiv eller værdier.

Download analyse (PDF)
* Preparations progress as planned
* Loan facilities provide support for 2025
* Our model suggests a fair value of SEK 16.29 per share

Lipum reported in its Q2 report that the manufacturing process of SOL-116 is nearing the final phase. The drug candidate is now being produced according to GMP standards, and the last batch is underway. At the same time, some of the company's major shareholders have provided short-term loans to finance the activities for the rest of the year. Shortly, we expect Lipum to announce a plan for financing the upcoming phase II study, which we now expect to start in Q2 2026.
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.